Dry Eye – Access & Reimbursement – Detailed, Expanded Analysis (US)

The U.S. market for dry eye disease (DED) therapies witnessed notable developments in 2019, including Novartis’s acquisition of Xiidra and the launch of Sun Ophthalmics’ Cequa at a competitive price to Allergan’s Restasis—the market leader in DED. Moreover, the anticipated generic entry of Restasis and the launch of novel therapies (Kala Pharmaceuticals’ Eysuvis, Bausch Health’s NOV03, ReGenTree’s RGN-259, Oyster Point’s OC-01, and Aldeyra Therapeutics’ ADX-102) in the near future could influence payers’ access and reimbursement decisions in DED. Therefore, drug marketers and developers must understand how U.S. payers, ophthalmologists, and optometrists react to the evolving market dynamics in the treatment of DED.

QUESTIONS ANSWERED

  • What formulary coverage do current drugs for moderate to severe DED receive on MCOs’ largest Medicare and commercial insurance plans? What approaches do payers use to manage utilization / costs of these drugs?
  • How do various factors, including clinical factors and payer restrictions, influence ophthalmologists’ and optometrists’ prescribing to moderate to severe DED patients covered by Medicare and commercial insurance plans?
  • What will be the anticipated impact of generic versions of Restasis, when available, on the formulary coverage and physician prescribing of drugs for moderate to severe DED?
  • How do payers plan to reimburse key emerging drugs for DED? What would cause payers to consider preferred status / formulary inclusion of these drugs? How will the prescriber landscape for moderate to severe DED evolve by 2022?

CONTENT HIGHLIGHTS

Geography: United States

Primary research: Survey of 100 U.S. ophthalmologists and optometrists, survey of 32 U.S. MCO PDs / MDs

Fingertip formulary: Formulary coverage and restrictions data for DED therapies by commercial plans covering approximately 164 million lives and Medicare Part D plans covering 35 million lives nationally.

Key drugs covered: Restasis, Restasis MultiDose, Xiidra, Cequa, Klarity-C, Eysuvis, NOV03, RGN-259, OC-01, ADX-102

Content highlights:

Reimbursement and contracting.

Access and prescribing.

Opportunities and challenges for emerging therapies.

Disease-specific special topic.

PRODUCT DESCRIPTION

U.S. Access & Reimbursement provides integrated brand- and disease-level insight on reimbursement dynamics and the impact of U.S. payer policy on physician prescribing behavior in the market access environment, including up-to-date analysis of drug coverage and restriction policies and payer and prescriber perspectives on key marketed drugs and receptivity to emerging therapies.

Table of contents

  • Dry Eye - Access & Reimbursement - Detailed, Expanded Analysis (US)
    • Access & Reimbursement Dry Eye Disease US April 2020

launch Related Market Assessment Reports